SNP recommendation guidelines: Difference between revisions
Jump to navigation
Jump to search
m NZ summary (also limited counter indicators) |
add TGA summary |
||
Line 41: | Line 41: | ||
* Devices regulated according to EU TDP, notified to MHRA, covered under GPSR. | * Devices regulated according to EU TDP, notified to MHRA, covered under GPSR. | ||
* Not currently licensed as medicines. | * Not currently licensed as medicines. | ||
* People who smoke but can't/won't quit. can reduce harm by smoking less or substituting temporarily. Harm reduction benefits are uncertain, but may inspire full quitting. | * People who smoke but can't/won't quit. can reduce harm by smoking less or substituting temporarily. | ||
* Harm reduction benefits are uncertain, but may inspire full quitting. | |||
|- | |||
|See also | |||
|[https://www.gov.uk/government/publications/nicotine-vaping-in-england-2022-evidence-update Nicotine vaping in England: 2022 evidence update] | |||
|} | |} | ||
Line 114: | Line 118: | ||
* Vaping is almost twice as effective as NRTs. | * Vaping is almost twice as effective as NRTs. | ||
* Goal: reducing the strength of your nicotine. | * Goal: reducing the strength of your nicotine. | ||
|} | |||
== Australia == | |||
=== Nicotine vaping products: Information for prescribers === | |||
{| class="wikitable" | |||
|+ | |||
! | |||
! | |||
|- | |||
|Link | |||
|https://www.tga.gov.au/resources/resource/guidance/nicotine-vaping-products-information-prescribers | |||
|- | |||
|Audience | |||
|GPs / PWS | |||
|- | |||
|By | |||
|Therapeutic Goods Administration | |||
|- | |||
|Considerations | |||
| | |||
* NVPs are Schedule 4 (prescription only) medicines, but remain 'unapproved'. | |||
* Their potential efficacy for smoking cessation is currently mixed. | |||
* [https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/supporting-smoking-cessation/tobacco-harm-reduction RACGP guideliness] apply, and NVPs are '''not first line treatment''' for smoking cessation. | |||
* Availability hinges on authorised prescriber, special access, or personal importation scheme. | |||
* TGA has a [https://www.tga.gov.au/resources/resource/guidance/authorised-prescribers-unapproved-nicotine-vaping-products list of authorised prescribers] (GPs). | |||
|} | |} |
Revision as of 15:42, 12 October 2022
Some countries and medical organizations have provided recommendations on which tobacco treatment cases might benefit from safer nicotine products as cessation option.
Canada
Lower-Risk Nicotine Use Guidelines (LRNUG)
Link | https://www.nicotinedependenceclinic.com/en/lower-risk-nicotine-user-guidelin-es |
Audience | GPs |
By | CAMH, Pharmacists for a Smoke-Free Canada (NGO) |
Considerations |
|
UK
NICE guidelines (NG209)
Link | https://www.nice.org.uk/guidance/ng209 |
Audience | GPs |
By | Gov UK / OHID |
Considerations |
|
See also | Nicotine vaping in England: 2022 evidence update |
Using e-cigarettes to stop smoking
Link | https://www.nhs.uk/live-well/quit-smoking/using-e-cigarettes-to-stop-smoking/ |
Audience | PWS |
By | National Health Service |
Considerations |
|
New Zealand
Vaping products: Information for health care workers and stop-smoking services
Link | https://www.health.govt.nz/our-work/preventative-health-wellness/tobacco-control/tobacco-control-information-practitioners/vaping-products-information-health-care-workers-and-stop-smoking-services |
Link | https://www.health.govt.nz/our-work/preventative-health-wellness/tobacco-control/vaping-smokefree-environments-and-regulated-products/position-statement-vaping |
Audience | GPs |
By | NZ Ministry of Health |
Considerations |
|
VapingFacts
Link | https://vapingfacts.health.nz/vaping-to-quit-smoking/ |
Audience | PWS |
By | NZ Ministry of Health |
Considerations |
|
Australia
Nicotine vaping products: Information for prescribers
Link | https://www.tga.gov.au/resources/resource/guidance/nicotine-vaping-products-information-prescribers |
Audience | GPs / PWS |
By | Therapeutic Goods Administration |
Considerations |
|